TANGULER TOLGA (EVP, Chief Commercial Officer) sold 6.3% of their position (2.31K shares) of ALNYLAM PHARMACEUTICALS, INC. on the open market
Open‑market sale worth $746.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
Common Stock
Shares
−106.00
Price / share
$319.03
Trade value
$33.82K
% of position
Common Stock
Shares
−102.00
Price / share
$320.01
Trade value
$32.64K
% of position
Common Stock
Shares
−215.00
Price / share
$320.81
Trade value
$68.97K
% of position
Common Stock
Shares
−289.00
Price / share
$321.82
Trade value
$93.01K
% of position
Common Stock
Shares
−350.00
Price / share
$323.01
Trade value
$113.05K
% of position
Common Stock
Shares
−767.00
Price / share
$323.84
Trade value
$248.39K
% of position
Common Stock
Shares
−272.00
Price / share
$324.88
Trade value
$88.37K
% of position
Common Stock
Shares
−208.00
Price / share
$325.67
Trade value
$67.74K
% of position
Net shares
−2.31K
Net value
-$745.98K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 3/4/2026 | S · Sale | −106.00 | $319.03 | $33.82K | 0.3% | 36.61K | 36.50K |
| Common Stock Direct | 3/4/2026 | S · Sale | −102.00 | $320.01 | $32.64K | 0.3% | 36.50K | 36.40K |
| Common Stock Direct | 3/4/2026 | S · Sale | −215.00 | $320.81 | $68.97K | 0.6% | 36.40K | 36.18K |
| Common Stock Direct | 3/4/2026 | S · Sale | −289.00 | $321.82 | $93.01K | 0.8% | 36.18K | 35.89K |
| Common Stock Direct | 3/4/2026 | S · Sale | −350.00 | $323.01 | $113.05K | 1.0% | 35.89K | 35.54K |
| Common Stock Direct | 3/4/2026 | S · Sale | −767.00 | $323.84 | $248.39K | 2.2% | 35.54K | 34.78K |
| Common Stock Direct | 3/4/2026 | S · Sale | −272.00 | $324.88 | $88.37K | 0.8% | 34.78K | 34.51K |
| Common Stock Direct | 3/4/2026 | S · Sale | −208.00 | $325.67 | $67.74K | 0.6% | 34.51K | 34.30K |
| Total | −2.31K | -$745.98K | ||||||